Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fasinumab in osteoarthritis pain
NCT03304379Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Oct 2017
- Primary completion
- Dec 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fasinumab in osteoarthritis (OA) (4 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Change From Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Scores at 24 weeks and Change From Baseline in WOMAC Physical Function Subscale Scores at 24 weeks. Started Oct 2017; status: completed.
02
Drugs
fasinumab
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT03304379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03304379.